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Background: Renal dysfunction is a prognostic factor in heart failure (HF) and is associated with an increased mortality risk and increased risk for 
re-admission. We examined risk and predictors of end-stage renal disease (ESRD) requiring renal replacement therapy in patients with HF followed in 
outpatient HF clinic.
methods: Patients with systolic HF were identified in The Danish Heart Failure Clinics Network database and new-onset ESRD from the Danish 
National Registry and Dialysis and Transplantation from 2002-2011. Patients with ESRD prior to referral to a HF clinic were excluded. Renal function 
was estimated by the Modification of Diet in Renal Disease Formula and patients grouped by eGFR according to Chronic Kidney Disease (CKD) 
stages: stage I+II: >60 ml/min/1.73m2, stage III: 60-30 ml/min/1.73m2, stage IV: 30-15 ml/min/1.73m2, stage V: <15 ml/min/1.73m2. Cox 
Proportional Hazard Models for time to ESRD, time to death or time to the combined endpoint of ESRD or death were constructed and predictors for 
ESRD identified.
results: A total of 8,204 patients were included in the analyses. Median age was 70 years (IQR 61-77), 28% were female, median left ventricular 
ejection fraction 30% (IQR 24-40) and median eGFR was 68 (IQR 51-85) ml/min/1.73m2. 41 patients developed ESRD (0.5% and 4.3 per 1000 
years of follow up). Baseline CKD stage III (HR 10.9; 95% CI: 3.0-40.8, P<0.001), CKD stage IV (HR 246.9; 95%CI: 66.3-914.6, P<0.001), CKD 
stage V (HR 996.4; 95%CI: 211.2-4499.9) hypertension (HR 2.1; 95% CI: 1.1-4.0, P=0.033) and age < 60 (HR 2.9, 95% CI: 1.3-6.3 P=0.007) were 
associated with time to ESRD. A total of 2,652 patients died (32.3 % and 101 per 1000 years of follow up). CKD stage III (HR 1.4; 95% CI: 1.3-1.5, 
P<0.001), CKD stage IV (HR 2.0; 95% CI: 1.8-2.4, P<0.001) and CKD stage V (HR 2.7; 95% CI: 1.7-4.3, P<0.001), diabetes (HR 1.3; 95% CI: 1.1-1.4, 
P<0.001) and age >70 (HR 1.7; 95% CI: 1.6-1.9, P<0.001) were associated with time to death or ESRD.
conclusion: ESRD is rare in outpatients with systolic HF and progression to ESRD is mainly observed in patients in CKD stage IV and V at the 
baseline visit in the HF clinic. CKD stage, age <60 years and hypertension identify patients with an increased risk for ESRD.
